Company aims to develop the next generation of engineered CHO cell lines to improve production of biotherapeutics

Next-generation gene editing system has applications in development of cell and gene therapies 

Agreement will expand open access resource, supporting genetic research globally

Envigo, a leading global research model supplier, enters the gene-edited research model field with the addition of Horizon’s business

First-to-market cell line-derived reference standard for myeloid blood cancers

Co-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation

First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening

First-to-market cfDNA Reference Standard specific for EGFR gene mutations adds to Horizon’s existing portfolio of cfDNA controls

First-to-market reagents enable native gene overexpression for meaningful gain-of-function studies

Allows the most comprehensive validation of oncology gene panels and large-scale exome sequencing assays

Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, today (Apr. 20) announced it has signed a supply and commercialization agreement with Thermo Fisher Scientific, the world leader in serving science.